Increases in ROS, ERK1/2 and STAT1 confer resistance and poor survival outcomes in patients on cisplatin.57 However, STAT3, Bcl-2 and Bcl-xL are crucial for the survival of cancer cells and thus inhibition by both cisplatin and (possibly EGCG) could account for the lack of anticancer interference with EGCG. Here, BCL2L1 is linked to cancer.